Caris Life Sciences (CAI) Q4 2025 earnings review
Staggering Margins and Profitability, but True-Ups Juice the Headline Number
Caris delivered a blockbuster Q4, with total revenue accelerating 125% YoY to $292.9M and net income surging to $82M. The company has decisively crossed into profitable territory, reversing years of heavy cash burn. Gross margins expanded an incredible 2,000 basis points to 75%, reflecting massive operating leverage on their sequencing platform. However, the headline 199% growth in molecular profiling revenue is distorted by $81M in prior-period true-ups. While the underlying clinical volume growth of 20% is stable, investors must separate the accounting catch-ups from the core operational momentum. Guidance for FY26 promises the $1B revenue milestone, indicating management believes the structural ASP (Average Selling Price) improvements are durable.
🐂 Bull Case
Gross margins hit 75% in Q4, up from 54% a year ago. The company’s unified WES/WTS (Whole Exome/Whole Transcriptome) platform is scaling beautifully, dropping almost all incremental commercial payer reimbursement directly to the bottom line.
Caris flipped from burning $245.2M in operating cash in FY24 to generating $83.2M in FY25. With $797.8M in cash and equivalents, the balance sheet is a fortress, eliminating dilution risk while funding aggressive R&D.
🐻 Bear Case
Molecular profiling revenue grew 199% in Q4, but clinical volume only grew 20%. The gap was heavily bridged by $81M in prior-period true-ups. Once these catch-up payments normalize, top-line growth will decelerate significantly.
Pharma R&D services revenue fell 70% YoY in Q4 to just $10.8M. This segment remains highly volatile and serves as a stark laggard against the core clinical diagnostics business.
⚖️ Verdict: 🟢
Bullish. While the massive true-ups artificially inflated Q4's revenue growth, the underlying structural transition to profitability is real. Expanding commercial coverage for MI Cancer Seek is permanently shifting the company's baseline ASP and margin profile.
Key Themes
Explosive Gross Margin Expansion
Accelerating. Gross margin scaled from 62.7% in 25Q2, to 68.0% in 25Q3, to an astonishing 75.0% in 25Q4. This is a textbook example of laboratory operating leverage: once the fixed costs of the sequencing infrastructure are covered, higher ASPs (driven by the $8,455 CMS rate for MI Cancer Seek) fall directly to gross profit.
The True-Up Distortion
A massive red flag for growth purists: Q4 included $81M in out-of-year revenue collections. When you subtract this $81M from the $282.1M in Q4 molecular profiling revenue, the segment's underlying revenue is $201.1M. This explains why management expects 2026 segment growth to decelerate to 21-22% (or 26-28% excluding the true-ups). The 199% YoY segment growth reported this quarter will never be repeated.
Pharma R&D Segment is a Severe Laggard
Reversing. Pharma research revenue plummeted from $35.5M in 24Q4 to $10.8M in 25Q4. While management previously cited 'project timing shifting,' the severe YoY contraction proves this revenue stream is highly unpredictable and currently acting as a drag on the broader corporate growth rate.
Caris Assure and Concurrent Testing
Liquid biopsy adoption remains a critical driver. Q4 saw 8,550 Caris Assure cases, representing over 16% of total volume. The clinical shift toward concurrent tissue and blood testing acts as an embedded catalyst, effectively increasing revenue per patient encounter without requiring new patient acquisition.
Macro: Commercial Payer Capitulation
The macro reimbursement environment for comprehensive genomic profiling has permanently shifted in Caris's favor. The operating cash flow swing—from negative $38.9M in 24Q4 to positive $44.8M in 25Q4—proves that commercial payers are finally remitting cash at contracted rates, solving the company's historical collections bottleneck.
Reinvestment Risk to Maintain Growth
With FY26 OpEx guided up 19-20% to nearly $600M, management is actively capping adjusted EBITDA margins to aggressively fund commercial expansion and the ACHIEVE early detection trials. Investors must monitor whether this massive spend yields proportional ROI, especially in the highly competitive early detection space.
Other KPIs
Reversing spectacularly from a burn of $41.2M in 24Q4. The business is now self-funding. Q4 Operating Cash Flow of $44.8M easily covered the $5.1M in CapEx.
Accelerating from $51.2M in 25Q3 and negative $23.0M in 24Q4. This metric best illustrates the transformation of the P&L as high-margin testing revenues scale against a stabilizing fixed-cost base.
Guidance
Decelerating from FY25's 97% growth to an implied 23-26% YoY growth rate. The deceleration is purely optical, driven by the normalization of the massive FY25 prior-period true-ups. Achieving $1B reflects immense scale.
Stable. This metric proves the underlying business is consistent. 20% volume growth on top of FY25's 199,300 cases implies roughly 239,000 cases in FY26.
Reversing/Accelerating compared to FY25. After finishing FY25 at just $45.3M (down from $63.1M in FY24), guiding to an $80M midpoint implies management expects a significant rebound or closure of delayed multi-year contracts.
Accelerating. Implies a 19-20% YoY increase from FY25's $494.1M. Management is leaning into commercial expansion and clinical trial pipelines (ACHIEVE-1 and 2), ensuring short-term profits are aggressively reinvested.
Key Questions
Dependence on Prior-Period Collections
With $81M in true-ups acting as a massive tailwind this quarter, what is the exact base ASP assumption built into the $1B revenue guidance for FY26?
Pharma Segment Visibility
Pharma R&D revenue collapsed 70% YoY in Q4 to $10.8M, yet guidance implies an $80M midpoint for FY26. What specific multi-year contracts or pipeline milestones give you the confidence to guide for this sharp rebound?
Margin Ceilings
Gross margins hit an incredible 75% in Q4. Is this the absolute ceiling given current reimbursement frameworks, or can increased automation and scale push this closer to 80% in FY26?
Caris Detect Commercialization
As you prepare to launch Caris Detect in H1 2026, what portion of the guided $590-$595M OpEx is dedicated to establishing the consumer/physician channel with Everlywell, and what is the target self-pay price point?